Intelligo

Private limited company · Øksnes

PHARMA NORGE AS

ActiveRetail sale of other food (47.270)

Founded
1 Oct 2017
Employees
23
Chief executive
Rune Meyer
Business address
Sørvåg, 8432 Alsvåg

The life line 2017–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 63.1m.

  1. Gjennomføring av fusjon§ 14
  2. Chair took office§ 07
  3. Managing director took office§ 07
  4. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

PHARMA NORGE AS is a private limited company in Øksnes, founded in 2017, in the industry retail sale of other food. The chief executive is Rune Meyer, and the chair of the board is Thomas Kristoffer Storvestre. In 2025 the company had NOK 63.1m in operating revenue and a net profit of NOK 8.1m. The largest owner is GLOBAL PHARMA GROUP AS with 88.4%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 13 Nov 2026

  • Number of employees 24 → 23
  • Number of employees 26 → 24
  • Number of employees 25 → 26
  • Annual accounts filed 2024 → 2025

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

1 point

  • OKEquity ratio 55.7%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue NOK 63.1m in 2025

Revenue

NOK 63.1m

+14.4% from 2024

20232025

Operating profit

NOK 7.5m

−51.5% from 2024

20232025

Net profit

NOK 8.1m

−42.9% from 2024

20232025

Equity

NOK 29.3m

−17.5% from 2024

20232025

Merger carried out 29 Jul 2024: the figures before and after are not the same business.

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Wages and social costs 13%
  • Depreciation 0%
  • Other operating costs 47%
  • Not specified in the source 28%
  • Left as operating result 12%

Of the net profit for 2025, NOK −6.2m stayed in the company. The rest, NOK 14.3m, is an assumed dividend.

The assumed dividend is derived by Intelligo from the change in equity, not stated by the source. Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 55.7%

RevenueNOK 63.1m Operating margin11.9% Equity ratio55.7% Revenue growth+14.4%
  • PHARMA NORGE AS, 2025
  • Industry median, assumed: NOK 3.4m · 2.5% · 27.8% · +10.0%

Equity NOK 29.3m56% of the assets (NOK 52.6m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 462 companies in 47.270 Retail sale of other food, not stated by the source.

Finances

§ 06 Accounts

8 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue63,09055,16240,478
Operating profit7,49715,4578,375
Profit before tax8,25015,3858,745
Net profit8,08914,1796,785
Total assets52,55348,25140,405
Equity29,26935,48332,469
Liabilities23,28312,7687,936

Source: the Register of Company Accounts, read 15 Nov 2026 · All 8 years →

Management and ownership

§ 07 Officers

5 officers now

The board: 1 member

Source: the Brønnøysund Register Centre, read 22 Oct 2026 · All 5 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

Daglig leder eller styrets leder hver for seg.

May sign for the company:

Daglig leder eller styrets leder hver for seg.

Power of procuration:

Daglig leder alene eller styrets leder alene.

The board has no authorisation in force now.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 2 Oct 2026

Management and ownership

§ 09 Owners

3 shareholders · largest 88.4%

OwnerShare
GLOBAL PHARMA GROUP AS
88.4%
PHARMA NORGE AS
3.5%
INFUTURE INVEST AS
1.6%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 3 owners →

Management and ownership

§ 10 Group

1 subsidiary

PHARMA NORGE AS parent company

Share held. Source: the Tax Administration's shareholder register, fetched 31 Jul 2026 · The whole group →

Management and ownership

§ 11 Portfolio

Holds shares in 1 company

Source: the Tax Administration's Register of Shareholders, read 31 Jul 2026 · The whole portfolio →

Management and ownership

§ 12 Network

20 connections

  • Person
  • Company

2 people link PHARMA NORGE AS to 17 other companies: Thomas Kristoffer Storvestre 13 and Rune Meyer 6.

Source: the Brønnøysund Register Centre, read 22 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

46 since 2017

Events per year

20172026

  • Notices35
  • Owners in and out6
  • Register changes5

Since 2017: 35 announcements, 5 register changes and 3 new and 3 former owners. Most happened in 2021 and 2022.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 2 Nov 2026. Register changes are Intelligo's own observations. · All 46 events →

Events and registers

§ 14 Notices

35, latest 20 Jul 2026

  • Godkjente årsregnskap
  • Godkjente årsregnskap
  • Styre

Source: The Brønnøysund Register Centre's announcements ↗, read 2 Nov 2026 · All 35 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 31 Oct 2017
  • VATRegistered
  • The Register of Business EnterprisesRegistered 31 Oct 2017
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Detaljhandel med naturprodukter og helsekostprodukter samt investeringsaktivitet og deltakelse i andre selskaper.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 47.270

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

7 questions

  • Who is the chief executive of PHARMA NORGE AS?
    Rune Meyer, since 2017. § 07
  • Who owns PHARMA NORGE AS?
    3 shareholders. The largest is GLOBAL PHARMA GROUP AS with 88.4%, PHARMA NORGE AS with 3.5% and INFUTURE INVEST AS with 1.6%. § 09
  • What was the revenue in 2025?
    NOK 63.1m in the company. § 06
  • Who can sign for PHARMA NORGE AS?
    Daglig leder eller styrets leder hver for seg. § 08
  • Who is the auditor?
    REVICOM AS, from 28 Aug 2019. § 07
  • Where is PHARMA NORGE AS based?
    Sørvåg, 8432 Alsvåg.
  • When was PHARMA NORGE AS founded?
    1 Oct 2017, registered in the Register of Business Enterprises 31 Oct 2017. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose